International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 2 , Pages 358-361 , 1 June 2008

Use of Local 111In-Capromab Pendetide Scan Results to Predict Outcome After Salvage Radiotherapy for Prostate Cancer

  • Bridget F. Koontz, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, NC
    • Duke Prostate Center, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests to: Bridget F. Koontz, M.D., Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710. Tel: (919) 668-7342; Fax: (919) 668-7345
    • ,
  • Vladimir Mouraviev, M.D., Ph.D.

      Affiliations

    • Duke Prostate Center, Duke University Medical Center, Durham, NC
    • Department of Surgery, Division of Urologic Surgery, Duke University Medical Center, Durham, NC
    • ,
  • Jeffrey L. Johnson, M.S.

      Affiliations

    • Duke Cancer Center Biostatistics, Duke University Medical Center, Durham, NC
    • ,
  • Janice Mayes, B.S.

      Affiliations

    • Department of Surgery, Division of Urologic Surgery, Duke University Medical Center, Durham, NC
    • ,
  • Stephanie H. Chen, B.S.

      Affiliations

    • Department of Surgery, Division of Urologic Surgery, Duke University Medical Center, Durham, NC
    • ,
  • Terence Z. Wong, M.D., Ph.D.

      Affiliations

    • Department of Radiology, Duke University Medical Center, Durham, NC
    • ,
  • Mitchell S. Anscher, M.D.

      Affiliations

    • Department of Radiation Oncology, Virginia Commonwealth University School of Medicine, Richmond, VA
    • ,
  • Leon Sun, M.D., Ph.D.

      Affiliations

    • Duke Prostate Center, Duke University Medical Center, Durham, NC
    • Department of Surgery, Division of Urologic Surgery, Duke University Medical Center, Durham, NC
    • ,
  • Judd Moul, M.D.

      Affiliations

    • Duke Prostate Center, Duke University Medical Center, Durham, NC
    • Department of Surgery, Division of Urologic Surgery, Duke University Medical Center, Durham, NC
    • ,
  • Thomas J. Polascik, M.D.

      Affiliations

    • Duke Prostate Center, Duke University Medical Center, Durham, NC
    • Department of Surgery, Division of Urologic Surgery, Duke University Medical Center, Durham, NC

Received 22 August 2007 ,Revised 4 October 2007 ,Accepted 6 October 2007.

References 

  1. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  2. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA. 2006;296:2329–2335
  3. Amling CL, Blute ML, Bergstralh EJ, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol. 2000;164:101–105
  4. Egawa S, Suyama K, Arai Y, et al. Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol. 2001;8:295–300
  5. Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. J Urol. 2007;177:1985–1991
  6. Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001;19:1030–1039
  7. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332
  8. Gronau E, Goppelt M, Harzmann R, et al. Prostate cancer relapse after therapy with curative intention: A diagnostic and therapeutic dilemma. Onkologie. 2005;28:361–366
  9. Sella T, Schwartz LH, Swindle PW, et al. Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology. 2004;231:379–385
  10. Sodee DB, Nelson AD, Faulhaber PF, et al. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005;3:230–238
  11. Wong TZ, Turkington TG, Polascik TJ, et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. 2005;184:676–680
  12. Kahn D, Williams RD, Haseman MK, et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284–289
  13. Levesque PE, Nieh PT, Zinman LN, et al. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology. 1998;51:978–984
  14. Nagda SN, Mohideen N, Lo SS, et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:834–840
  15. Paulson DF, Vieweg JW. Radical perineal prostatectomy: A model for evaluating local response of prostate therapy. Crit Rev Oncol Hematol. 2002;43:135–139
  16. Vis AN, Schroder FH, van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol. 2006;50:258–265
  17. Bermejo CE, Coursey J, Basler J, et al. Histologic confirmation of lesions identified by Prostascint scan following definitive treatment. Urol Oncol. 2003;21:349–352discussion, 353
  18. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002;94:987–996
  19. Sodee DB, Ellis RJ, Samuels MA, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: Semiquantitative correlation with prostatic biopsy results. Prostate. 1998;37:140–148
  20. Ellis RJ, Kaminsky DA. Fused radioimmunoscintigraphy for treatment planning. Rev Urol. 2006;8(Suppl. 1):S11–S19
  21. Sodee DB, Malguria N, Faulhaber P, et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology. 2000;56:988–993
  22. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715–1721
  23. Proano JM, Sodee DB, Resnick MI, et al. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol. 2006;175:1668–1672

 Presented in part at the 2007 American Society of Clinical Oncology Prostate Symposium, February 22–24, 2007, Orlando, FL.

 Conflict of interest: T.J. Polascik is a funded investigator for Cytogen Corp. J.Moul is a paid lecturer and consultant for Cytogen.

PII: S0360-3016(07)04443-4

doi: 10.1016/j.ijrobp.2007.10.020

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 2 , Pages 358-361 , 1 June 2008

Article Tools

* Image Usage & Resolution